9 terminated. 9 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Terminated 9 |
| Phase 2 | 4 | Terminated 4 |
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose - Polypoidal Choroidal Vasculopathy | Phase 2 / Phase 3 | Terminated | Sun Yat-sen University | 5 | 2018-08-01 | 2019-09-19 |
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy E10030, bevacizumab or aflibercept, E10030 sham injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 645 | 2014-05-01 | 2024-10-31 |
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 627 | 2013-08-01 | 2024-10-30 |
| A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy E10030, ranibizumab, E10030 sham intravitreal injection - Age-Related Macular Degeneration | Phase 3 | Terminated | Ophthotech Corporation | 619 | 2013-08-01 | 2024-10-30 |
| Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab ranibizumab - Age-Related Macular Degeneration | Phase 2 / Phase 3 | Terminated | University of California, San Diego | 20 | 2011-07-01 | 2019-08-28 |
| Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) Verteporfin Photodynamic Therapy, Ranibizumab, Placebo - Macular Degeneration, Choroidal Neovascularization | Phase 2 / Phase 3 | Terminated | Novartis | 255 | 2007-05-01 | 2011-04-21 |
| Efficacy of Retreatments With Intravitreal Bevacizumab Intravitreal injection of Bevacizumab - Age Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Terminated | Asociación para Evitar la Ceguera en México | 20 | 2006-05-01 | 2024-06-03 |
| Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment Intravitreal Bevacizumab - Diabetic Proliferative Retinopathy, Vascular Vein Oclussion | Phase 2 / Phase 3 | Terminated | Asociación para Evitar la Ceguera en México | 2005-12-01 | 2024-06-03 | |
| Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Intravitreal Bevacizumab - Angioid Streaks, Choroidal Neovascularization | Phase 3 | Terminated | Asociación para Evitar la Ceguera en México | 2005-11-01 | 2024-06-03 |
Choroidal Neovascularization (8) · Macular Degeneration (6) · Angioid Streaks (1) · Neovascularization, Pathologic (1) · Polypoidal Choroidal Vasculopathy (1)
Choroid Diseases (9) · Eye Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Uveal Diseases (9) · Neovascularization, Pathologic (8) · Retinal Diseases (7) · Retinal Degeneration (6) · Choroidal Neovascularization (1)
Ranibizumab (5) · E10030 aptamer (3) · salicylhydroxamic acid (3) · Bevacizumab (1) · Verteporfin (1) · aflibercept (1)
Asociación para Evitar la Ceguera en México (3) · Ophthotech Corporation (3) · Novartis (1) · Sun Yat-sen University (1) · University of California, San Diego (1)
United States (4) · Austria (3) · France (3) · Germany (3) · Hungary (3) · Italy (3) · Poland (3) · Spain (3) · Argentina (2) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Colombia (2) · Czechia (2)
Griselda Alvarez-Rivera, MD (1) · Henry Ferreyra, MD (1) · Hugo Quiroz-Mercado, MD (1) · Jans Fromow-Guerra, MD PhD (1) · Lin Lu, MD, phD (1) · Veronica Kon-Jara, MD (1)
PMID 30957581, PMID 14557174, PMID 16897221, PMID 19726427, PMID 22424834, PMID 22426346, PMID 23352196, PMID 25079064, PMID 25646029